# PK and PD Within-Subject Variability of a Single Dose of Afrezza Inhaled Technosphere Insulin in Patients With Diabetes Mellitus Type 1 (T1DM)

> **NCT02485327** · PHASE1 · COMPLETED · sponsor: **Mannkind Corporation** · enrollment: 22 (actual)

## Conditions studied

- Type 1 Diabetes Mellitus

## Interventions

- **DRUG:** Technosphere Insulin SAR439065 Afrezza®

## Key facts

- **NCT ID:** NCT02485327
- **Lead sponsor:** Mannkind Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07
- **Primary completion:** 2015-11
- **Final completion:** 2015-11
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2017-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02485327

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02485327, "PK and PD Within-Subject Variability of a Single Dose of Afrezza Inhaled Technosphere Insulin in Patients With Diabetes Mellitus Type 1 (T1DM)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02485327. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*